SCHEMBL4492022

SCHEMBL4492022

Cc1[nH]c(C)c(-c2c[nH]c(-c3cccc(C(F)(F)F)c3)cc2=O)c(=O)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.41
SLC2A1 P11166 1/20 0.39
SLC11A2 P49281 1/20 0.38
IKBKB O14920 1/20 0.37
PIN1 Q13526 1/20 0.37
SCN2A Q99250 3/20 0.37
CDC7 O00311 1/20 0.37
XDH P47989 1/20 0.37
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35
MAPK14 Q16539 1/20 0.35
NPY5R Q15761 1/20 0.35
KDM4E B2RXH2 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4565035 0.89 TNKS (0.39) MAPTSLC2A1SLC11A2NPY5RSMN1; SMN2
SCHEMBL4493394 0.87 SLC2A1 (0.52) MAPTSLC2A1SLC11A2IKBKBPIN1
SCHEMBL4490544 0.85 BRD4 (0.39) MAPTHTTMEN1NPC1RAB9A
SCHEMBL4471113 0.85 XDH (0.40) XDHNPY5RLMNAALDH1A1THRB
SCHEMBL4491224 0.84 DAO (0.34) MAPTSLC2A1MEN1ALDH1A1PKM
SCHEMBL4472776 0.84 BIRC5 (0.38) MAPTSLC2A1CYP1A2CYP2C19MEN1
SCHEMBL4486777 0.84 SCN2A (0.40) MAPTSLC11A2IKBKBPIN1SCN2A
SCHEMBL4486317 0.83 MAPT (0.35) MAPTSLC2A1KDM4ECYP1A2CYP3A4
SCHEMBL4485647 0.83 HSD11B1 (0.35) MAPTSLC2A1CYP1A2CYP3A4CYP2C9
SCHEMBL4475367 0.81 ADORA2A (0.39) MAPTSLC2A1KDM4ECYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP MAPT 1942/4885SLC2A1 2278/4885SLC11A2 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.